MedKoo Cat#: 592630 | Name: Bitolterol mesylate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bitolterol, (3-4 diester colterol) is a new beta 2-adrenergic agonist. Since it in itself is biologically inactive, bitolterol is considered a pro-drug. When administered it is activated within the lung by esterase hydrolysis to the active compound colterol catecholamine N-t-butyl-arterenol). In preclinical and clinical studies to date, bitolterol has proved to be an effective bronchodilator for adult and pediatric patients with chronic stable asthma and for some with chronic obstructive pulmonary disease. Bitolterol has been compared with other beta 2 agents, including isoproterenol, metaproterenol and albuterol. There is no evidence for cardiotoxicity when bitolterol is used in combination with theophylline in human studies. It is effective for control of exercise-induced asthma.

Chemical Structure

Bitolterol mesylate
Bitolterol mesylate
CAS#30392-41-7 (mesylate)

Theoretical Analysis

MedKoo Cat#: 592630

Name: Bitolterol mesylate

CAS#: 30392-41-7 (mesylate)

Chemical Formula: C29H35NO8S

Exact Mass: 0.0000

Molecular Weight: 557.66

Elemental Analysis: C, 62.46; H, 6.33; N, 2.51; O, 22.95; S, 5.75

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
Synonym
Bitolterol mesylate; Bitolterol; Bitolterolum; S 1540; S-1540; S1540; Win 32,784; Win32784; Win 32784; Win-32784; Tornalate; Effectin;
IUPAC/Chemical Name
4-(2-(tert-butylamino)-1-hydroxyethyl)-1,2-phenylene bis(4-methylbenzoate) methanesulfonate
InChi Key
HODFCFXCOMKRCG-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H31NO5.CH4O3S/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21;1-5(2,3)4/h6-16,23,29-30H,17H2,1-5H3;1H3,(H,2,3,4)
SMILES Code
OC(CNC(C)(C)C)C1=CC=C(C(OC(C2=CC=C(C=C2)C)=O)=C1)OC(C3=CC=C(C=C3)C)=O.CS(=O)(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 557.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Nathan RA, Bernstein IL, Bronsky EA, Bush RK, Chervinsky P, Condemi JJ, Dockhorn RJ, Pinnas JL, Repsher LH. Comparison of the bronchodilator effects of nebulized bitolterol mesylate and isoproterenol hydrochloride in steroid-dependent asthma. J Allergy Clin Immunol. 1987 May;79(5):822-9. PubMed PMID: 3571773. 2: Nathan RA, Bodman SF, Storms WW, Mingo TS. Bitolterol mesylate aerosol in adults with steroid-dependent asthma: a comparison with isoproterenol hydrochloride aerosol. Ann Allergy. 1986 Jun;56(6):494-9. PubMed PMID: 3717716. 3: Kemp JP, Pinnas JL, Tinkelman DG, Meltzer EO, Campbell SC, Orgel HA, Welch MJ, Mingo TS. Comparison of bronchodilator responses with bitolterol mesylate solution with the use of two different nebulizer systems in asthma. J Allergy Clin Immunol. 1986 Mar;77(3):509-15. PubMed PMID: 3950254. 4: Bierman CW, Kemp JP, Nathan RA. Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma. Ann Allergy Asthma Immunol. 1996 Jan;76(1):27-35. PubMed PMID: 8564625. 5: Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP. Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma. Ann Allergy. 1994 Mar;72(3):209-16. PubMed PMID: 8129213. 6: Walker SB, Bierman CW, Pierson WE, Shapiro GG, Furukawa CT, Mingo TS. Bitolterol mesylate in exercise-induced asthma. J Allergy Clin Immunol. 1986 Jan;77(1 Pt 1):32-6. PubMed PMID: 3944373. 7: Hunke WA, Yu AB. Particle-size distribution of bitolterol mesylate solution delivered by four compressed-air nebulizer devices. Am J Hosp Pharm. 1987 Jun;44(6):1392-6. PubMed PMID: 3618619. 8: Walker SB, Kradjan WA, Bierman CW. Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37. Review. PubMed PMID: 3895171. 9: Kass I, Mingo TS. Bitolterol mesylate (WIN 32784) aerosol. A new long-acting bronchodilator with reduced chronotropic effects. Chest. 1980 Aug;78(2):283-7. PubMed PMID: 6995040. 10: Pinnas JL, Bernstein IL, Bronsky EE, Bush RK, Chervinsky P, Condemi JJ, Dockhorn RJ, Nathan RA, Repsher LH, Bhatt BD, et al. Multicenter study of bitolterol and isoproterenol nebulizer solutions in nonsteroid-using patients. J Allergy Clin Immunol. 1987 May;79(5):768-75. PubMed PMID: 3571768. 11: Pinnas JL, Bhatt BD, Campbell SC, Kemp JP, Tinkelman DG. Dose-response study of nebulized bitolterol mesylate solution in asthmatic patients. Chest. 1987 Apr;91(4):533-9. PubMed PMID: 3549173. 12: Kemp JP, Chervinsky P, Orgel HA, Meltzer EO, Noyes JH, Mingo TS. Concomitant bitolterol mesylate aerosol and theophylline for asthma therapy, with 24 hr electrocardiographic monitoring. J Allergy Clin Immunol. 1984 Jan;73(1 Pt 1):32-43. PubMed PMID: 6693665. 13: Messina MS. Retrospective study of bitolterol mesylate in the treatment of conditions associated with reversible bronchospasm. Adv Ther. 1995 May-Jun;12(3):157-63. PubMed PMID: 10155050. 14: Kemp JP, Orgel HA, Grossman J, Reed CE, Tinkelman DG, Webb DR, Ziment I. Outpatient management of asthma with regular nebulized beta agonists: comparison of bitolterol mesylate and isoproterenol. Ann Allergy. 1987 Jul;59(1):17-20. PubMed PMID: 3300436. 15: Wilson TD, Fogarty DF. The effect of column age on system suitability parameters for an HPLC assay of bitolterol mesylate aerosols. J Chromatogr Sci. 1988 Feb;26(2):60-6. PubMed PMID: 3350902. 16: Kelly HW. New beta 2-adrenergic agonist aerosols. Clin Pharm. 1985 Jul-Aug;4(4):393-403. Review. PubMed PMID: 2864159. 17: Orgel HA, Kemp JP, Tinkelman DG, Webb DR Jr. Bitolterol and albuterol metered-dose aerosols: comparison of two long-acting beta 2-adrenergic bronchodilators for treatment of asthma. J Allergy Clin Immunol. 1985 Jan;75(1 Pt 1):55-62. PubMed PMID: 3968329. 18: Petty TL, Scoggin CH, Rollins DR, Repsher LH. Bitolterol compared to isoproterenol in advanced chronic obstructive pulmonary disease. Chest. 1984 Sep;86(3):404-8. PubMed PMID: 6380974. 19: Dal Negro R, Cogo AL, Pomari C, Turati C, Turco P, Allegra L. Effects of salbutamol and bitolterol mesilate on pO2 levels in asthmatic patients and healthy volunteers. Arzneimittelforschung. 1992 Jul;42(7):959-61. PubMed PMID: 1418062. 20: Friedel HA, Brogden RN. Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease. Drugs. 1988 Jan;35(1):22-41. Review. PubMed PMID: 3278878.